Therapeutic trial by taurine for intractable childhood epilepsies

Area of Science:

• Neuroscience
• Biochemistry
• Pediatrics

Background:

• Intractable epilepsy in children presents significant treatment challenges.
• Anticonvulsant medications are often insufficient for complete seizure control.
• Investigating novel therapeutic agents like taurine is crucial for pediatric epilepsy management.

Observation:

• Taurine was administered orally to 25 children (4 months–12 years) with daily frequent seizures.
• Doses ranged from 0.05 to 0.3 g/kg, with 12 patients also receiving probenecid.
• Seizure frequency, electroencephalographic (EEG) abnormalities, and taurine levels were monitored.

Findings:

• Complete seizure control occurred in one Lennox syndrome case; others had limited or temporary seizure reduction.
• EEG abnormalities improved in only one patient alongside clinical seizure control.
• Taurine supplementation did not alter CSF or serum taurine levels in most patients, but increased urinary excretion.
• Side effects including drowsiness and ataxia were observed in four patients.

Implications:

• Taurine shows limited efficacy as an adjunctive therapy for intractable childhood epilepsy.
• Further research is needed to understand the mechanisms and identify potential responders.
• Probenecid co-administration did not appear to enhance taurine's therapeutic effects significantly.